公司概覽
業務類別 Biotechnology
業務概覽 Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
公司地址 780 Brannan Street, San Francisco, CA, USA, 94103
電話號碼 +1 415 651-3316
傳真號碼 --
公司網頁 https://www.olema.com
員工數量 131
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Sean P. Bohen, M.D.,PhD Director, President and Chief Executive Officer 美元 699.92K 13/08/2026
Ms. Shawnte M. Mitchell, J.D. Chief Legal Officer and Corporate Secretary 美元 391.88K 29/04/2026
Dr. David C. Myles, PhD Chief Scientific Officer -- 29/04/2026
Dr. Naseem Zojwalla, M.D. Chief Medical Officer -- 29/04/2026
Mr. Jason O'Byrne Chief Financial Officer -- 13/08/2026
Ms. Sasha Lu Austin Vice President, Finance and Controller -- 16/03/2026
 
董事會成員
董事會 職務 更新日期
Mr. Andrew S. Rappaport Independent Director 29/04/2026
Ms. Cynthia M. Butitta Independent Director 29/04/2026
Mr. Ian T. Clark Chairman of the Board 29/04/2026
Dr. Sandra J. Horning, M.D. Independent Director 29/04/2026
Mr. Scott Garland Independent Director 29/04/2026
Dr. Sean P. Bohen, M.D.,PhD Director, President and Chief Executive Officer 13/08/2026
Dr. Graham Walmsley, M.D.,PhD Independent Director 29/04/2026
Ms. Yi Larson Independent Director 29/04/2026
Dr. Cyrus L. Harmon, PhD Independent Director 29/04/2026
Dr. Prakash Raman, PhD Independent Director 29/04/2026
 
所屬ETF (更新日期: 14/11/2026 02:15)
代號 名稱 佔比% ▼ 持有日期
XBIState Street® SPDR® S&P® Biotech ETF2.63%30/10/2026
IWMiShares Russell 2000 ETF2.26%30/10/2026
IWNiShares Russell 2000 Value ETF0.70%30/10/2026
IBBiShares Biotechnology ETF0.63%30/10/2026
FESMFidelity Enhanced Small Cap Core ETF0.55%30/10/2026
VTWOVanguard Russell 2000 ETF0.52%30/09/2026
SCHASchwab US Small-Cap ETF™0.43%31/10/2026
DFASDimensional US Small Cap ETF0.29%02/10/2026
IWCiShares Micro-Cap ETF0.27%30/10/2026
DFACDimensional US Core Equity 2 ETF0.24%02/10/2026
VHTVanguard Health Care ETF0.19%30/09/2026
IWOiShares Russell 2000 Growth ETF0.14%30/10/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.14%30/10/2026
SBIOALPS Medical Breakthroughs ETF0.12%30/10/2026
LABUDirexion Daily S&P Biotech Bull 3X ETF0.11%31/10/2026
CANCTema Oncology ETF0.10%30/10/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.08%30/10/2026
VTWVVanguard Russell 2000 Value ETF0.07%30/09/2026
SCHBSchwab US Broad Market ETF0.06%31/10/2026
OPTZOptimize Strategy Index ETF0.05%30/10/2026
 1    2    3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.